Skip to main
  1. Stocks
  2. Cingulate
  3. Forecast
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate is viewed favorably because its June 2 CRL for CTx-1301 cited only CMC issues, not safety or efficacy concerns, preserving the core regulatory value of its once-daily ADHD program and supporting a credible resubmission path. The company’s $28.4M cash balance in 2Q26 provides runway into mid-2027, while the July 21 Prasco distribution agreement and patent protection through 2042 strengthen its commercialization and intellectual-property profile. With ADHD medication sales reaching about $18 billion in 2020 and CTx-1301/CTx-1302 targeting large pediatric and adult populations, the platform offers meaningful upside if approval is achieved after resubmission.

Bears say

Cingulate is viewed negatively because its lead asset CTx-1301 still faces unresolved FDA issues, including three Form 483 observations and the need for both CMC and facility remediation, making approval dependent on Bend Bioscience execution and a possible second inspection. The company’s launch outlook is therefore fragile, with any delay potentially pushing commercialization beyond the currently projected 3Q27, while its broader pipeline also carries regulatory, clinical, reimbursement, and partnership risks. Financially, it remains pre-revenue and unprofitable, reporting a $9.3 million net loss in Q1 2026 and a $5.9 million net loss in Q2 2026, with no guidance and ongoing dilution risk.

Cingulate (CING) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Cingulate (CING) Analyst Forecast & Price Prediction

Get the latest Cingulate (CING) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Cingulate (CING)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Cingulate (CING) Analyst Forecast & Price Prediction

Get the latest Cingulate (CING) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Cingulate (CING)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CING stock data and trends